J.P. Morgan Asset Management Chief Market Strategist for the Americas Gabriela Santos said that she would allocate $7,000 to ...

Pharmaceutical stocks slumped after President Donald Trump sent letters to 17 drugmakers with an ultimatum to reduce drug ...

Explore market-impacting Trump administration moves, from drug pricing reforms targeting pharma giants to Swiss tariff hikes.

JNJ edges out AZN following Q2 results with raised guidance, stronger estimate revisions and a more attractive valuation.

Shares of European pharmaceutical companies sold off on Friday after President Donald Trump issued letters to 17 companies, ...

President Donald Trump has sent letters to the CEOs of 17 pharmaceutical companies demanding action to address high prescription drug costs in the United States, the White House announced Thursday.

The Trump administration has proposed a pilot initiative to address controversy over the 340B drug discount program.

Investors say that J&J knowingly inflated its stock value by hiding information about asbestos contamination of its talc ...

A Boston jury awarded a Massachusetts family $42.6 million in a lawsuit against Johnson & Johnson, claiming the company's ...

These four Dividend Aristocrats are Buy-rated sector leaders with yields above 3%. Passive income investors can buy and hold ...

Thanks to its international presence, […] JNJ jumps over 6% on Q2 earnings beat and full ... J&J announced in late 2021 that it was splitting its consumer health division from the pharmaceutical and ...

Here are four high-yield blue-chip pharmaceutical stocks positioned to outperform and offer huge total return potential.